CL2020002611A1 - Una composición farmacéutica en polvo seco para inhalación que comprende una hormona tiroidea - Google Patents

Una composición farmacéutica en polvo seco para inhalación que comprende una hormona tiroidea

Info

Publication number
CL2020002611A1
CL2020002611A1 CL2020002611A CL2020002611A CL2020002611A1 CL 2020002611 A1 CL2020002611 A1 CL 2020002611A1 CL 2020002611 A CL2020002611 A CL 2020002611A CL 2020002611 A CL2020002611 A CL 2020002611A CL 2020002611 A1 CL2020002611 A1 CL 2020002611A1
Authority
CL
Chile
Prior art keywords
dry powder
inhalation
thyroid hormone
pharmaceutical composition
powder pharmaceutical
Prior art date
Application number
CL2020002611A
Other languages
English (en)
Inventor
Ioulia Tseti
Original Assignee
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66439988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002611(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ioulia Tseti filed Critical Ioulia Tseti
Publication of CL2020002611A1 publication Critical patent/CL2020002611A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a composiciones en polvo seco, adecuadas para su inhalación a través de un dispositivo de inhalación apropiado, comprendiendo un fármaco de hormona tiroidea y un azúcar no reductor o azúcar alcohólico como único portador.<br /> Las preparaciones de la invención muestran una estabilidad más alta que las correspondientes con lactosa monohidrato, un portador normalmente usado para preparaciones en polvo seco.
CL2020002611A 2018-04-16 2020-10-09 Una composición farmacéutica en polvo seco para inhalación que comprende una hormona tiroidea CL2020002611A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18167617 2018-04-16
EP19386017 2019-03-22

Publications (1)

Publication Number Publication Date
CL2020002611A1 true CL2020002611A1 (es) 2021-02-05

Family

ID=66439988

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002611A CL2020002611A1 (es) 2018-04-16 2020-10-09 Una composición farmacéutica en polvo seco para inhalación que comprende una hormona tiroidea

Country Status (22)

Country Link
US (1) US11786460B2 (es)
EP (1) EP3781126B1 (es)
JP (1) JP7239604B2 (es)
KR (1) KR102913096B1 (es)
CN (1) CN111954518B (es)
AU (1) AU2019256584B2 (es)
BR (1) BR112020019711A2 (es)
CA (1) CA3095872A1 (es)
CL (1) CL2020002611A1 (es)
DK (1) DK3781126T3 (es)
ES (1) ES2916413T3 (es)
HR (1) HRP20220715T1 (es)
HU (1) HUE059420T2 (es)
IL (1) IL278011B2 (es)
LT (1) LT3781126T (es)
MX (1) MX2020010928A (es)
PL (1) PL3781126T3 (es)
RS (1) RS63439B1 (es)
SA (1) SA520420369B1 (es)
SI (1) SI3781126T1 (es)
WO (1) WO2019201712A1 (es)
ZA (1) ZA202006371B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121002055A (zh) * 2023-02-07 2025-11-21 吉纳斯生命科学公司 包括猪甲状腺粉的固体剂型及其制造和使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
HUP0301416A2 (hu) 2000-07-06 2003-09-29 Delsys Pharmaceutical Corporation Javított tiroid hormon gyógyszerformák
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
DE602004012904T2 (de) * 2004-11-18 2009-04-16 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Trockenpulver mit levothyroxin-natrium mit verabreichung über einen inhalator
HRP20100633T1 (hr) 2005-07-21 2011-01-31 F. Hoffmann - La Roche Ag Derivati piridazinona kao agonisti receptora tiroidnih hormona
JP2009519972A (ja) 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
RU2585101C2 (ru) 2010-04-01 2016-05-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ приготовления частиц носителя для сухих порошков для ингаляции
EP2611416B1 (en) 2010-09-03 2015-08-19 Pharmaterials Ltd. Pharmaceutical composition suitable for use in a dry powder inhaler
IN2014MU03703A (es) 2014-11-21 2015-07-22

Also Published As

Publication number Publication date
PL3781126T3 (pl) 2022-10-10
SA520420369B1 (ar) 2024-03-28
EP3781126B1 (en) 2022-05-04
LT3781126T (lt) 2022-07-25
HRP20220715T1 (hr) 2022-09-30
EP3781126A1 (en) 2021-02-24
JP7239604B2 (ja) 2023-03-14
AU2019256584A1 (en) 2020-10-08
KR102913096B1 (ko) 2026-01-14
RS63439B1 (sr) 2022-08-31
US11786460B2 (en) 2023-10-17
MX2020010928A (es) 2020-11-06
JP2021520397A (ja) 2021-08-19
KR20210002542A (ko) 2021-01-08
IL278011B2 (en) 2024-12-01
WO2019201712A1 (en) 2019-10-24
SI3781126T1 (sl) 2022-10-28
IL278011A (en) 2020-11-30
CN111954518B (zh) 2024-04-05
BR112020019711A2 (pt) 2021-02-09
AU2019256584B2 (en) 2025-01-23
CN111954518A (zh) 2020-11-17
IL278011B1 (en) 2024-08-01
ES2916413T3 (es) 2022-06-30
HUE059420T2 (hu) 2022-11-28
CA3095872A1 (en) 2019-10-24
ZA202006371B (en) 2022-12-21
DK3781126T3 (da) 2022-06-13
US20210077391A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
IL284913A (en) Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
EP4053151A4 (en) Keratin bd-1, preparation method, and pharmaceutical composition and use thereof
CU20210077A7 (es) Extractos bacterianos estables como fármacos
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
BR112016007410A8 (pt) conjugados de sn-38 de liberação lenta, formulações farmacêuticas e usos dos conjugados
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MY199762A (en) Moisturizing topical preparation
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
JOP20170127A1 (ar) صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
CL2016000154A1 (es) Composición para la gestión de las náuseas y los vómitos.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
BR112015028302A2 (pt) formulação de pastilha de nicotina
SA520420369B1 (ar) تركيبة مسحوق جاف صيدلانية للاستنشاق تشتمل على هرمون درقي
CL2013000332A1 (es) Matriz impregnable de origen vegetal, animal o sintetica que contiene un compuesto antimicrobiano distribuido homogeneamente; procedimiento para impregnar un compuesto en una matriz; uso de dicha matriz para preparar soportes solidos de uso cosmetico, farmaceutico, medico o veterinario.
AR114768A1 (es) Una composición farmacéutica seca en polvo para inhalación que comprende una hormona tiroidea
ECSP21079422A (es) Método para preparar formulaciones de péptidos estables
CY1125336T1 (el) Μια φαρμακευτικη συνθεση ξηρης σκονης για εισπνοη που περιλαμβανει μια θυρεοειδικη ορμονη